FINWIRES · TerminalLIVE
FINWIRES

加拿大皇家银行表示,受需求担忧影响,亿滋国际短期内面临不利局面。

-- 加拿大皇家银行资本市场(RBC Capital Markets)周五在对亿滋国际(Mondelez International,股票代码:MDLZ)第一季度业绩的预览报告中指出,该公司在发达市场面临挑战,且中东冲突对需求的威胁日益加剧,导致其近期前景更为谨慎。 报告称,由于亿滋国际在中东地区直接销售产品,其投入成本和营收均“相对容易受到”中东冲突的影响。报告指出,亿滋国际可能面临中东地区对美国产品的抵制,以及“由于能源短缺导致全球其他地区流动性下降”。 在美国,截至目前,扫描仪数据显示本季度销量增长1.6%,环比增长约80个基点,但与两年平均水平相比下降约60个基点。 加拿大皇家银行表示,饼干是亿滋国际最大的产品类别,约占美国销售额的45%,但其销量仍在下滑。报告还指出,在美国,亿滋国际还面临着来自规模较小的竞争对手的“巨大竞争压力”,尤其是在巧克力棒领域。 加拿大皇家银行指出,该公司营收“略低于”市场普遍预期。 与此同时,大宗商品成本仍然是一大挑战,尽管该公司采取的套期保值策略比大多数同行更为成熟,而且随着可可价格的下跌,亿滋国际可能已经度过了最艰难的时期。 加拿大皇家银行维持对亿滋国际的“跑赢大盘”评级,目标价为63美元。

Price: $57.68, Change: $-0.04, Percent Change: -0.06%

Related Articles

Asia

Update: Origin Energy Reports Lower March Quarter Production; Shares Fall 3%

(Updates to add stock movement in the headline and last paragraph)Origin Energy (ASX:ORG) reported March quarter production of 164.5 petajoules, down from 167.1 petajoules a year earlier, according to a Monday filing with the Australian bourse.The company reported commodity revenue of AU$1.86 billion for the quarter, down from AU$ 2.31 billion a year ago, per the filing.Origin Energy also said its electricity sales volume increased 4% from a year earlier amid "strong growth" in business volumes driven largely by the data-center sector.The company's shares fell 3% in recent Monday trade.

$ASX:ORG
Asia

Alterity Therapeutics Secures US FDA Support for ATH434 Phase Three Program

Alterity Therapeutics (ASX:ATH) said it received positive feedback from a second type C meeting with the US Food and Drug Administration (FDA) on its planned phase three program for drug candidate ATH434, aimed at treating multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.MSA is a progressive neurodegenerative disorder affecting autonomic and motor function with no approved disease-modifying therapies.The US FDA provided supportive written feedback on the program's chemistry, manufacturing, and controls, complementing earlier guidance from a separate type C meeting on clinical pharmacology and non-clinical development, the filing added.

$ASX:ATH
Asia

Xinyuan Property Management's CFO Resigns

Xinyuan Property Management Service's (HKG:1895) chief financial officer, Wang Yong, has resigned, effective April 26, according to a Monday Hong Kong bourse filing.Wang stepped down to devote more time to personal commitments, the company said.The company said the resignation will not affect its normal operations, with Wang's duties to be reallocated internally on an interim basis.Xinyuan Property Management added that it is seeking a suitable replacement for the chief financial officer role.

$HKG:1895